185 related articles for article (PubMed ID: 23272904)
1. Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer.
Pressly ED; Pierce RA; Connal LA; Hawker CJ; Liu Y
Bioconjug Chem; 2013 Feb; 24(2):196-204. PubMed ID: 23272904
[TBL] [Abstract][Full Text] [Related]
2. Design and Modular Construction of a Polymeric Nanoparticle for Targeted Atherosclerosis Positron Emission Tomography Imaging: A Story of 25% (64)Cu-CANF-Comb.
Woodard PK; Liu Y; Pressly ED; Luehmann HP; Detering L; Sultan DE; Laforest R; McGrath AJ; Gropler RJ; Hawker CJ
Pharm Res; 2016 Oct; 33(10):2400-10. PubMed ID: 27286872
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET.
Liu Y; Pressly ED; Abendschein DR; Hawker CJ; Woodard GE; Woodard PK; Welch MJ
J Nucl Med; 2011 Dec; 52(12):1956-63. PubMed ID: 22049461
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Targeted Nanoparticle Assemblies for Atherosclerosis Imaging with Positron Emission Tomography and Potential for Clinical Translation.
Liu Y; Luehmann HP; Detering L; Pressly ED; McGrath AJ; Sultan D; Nguyen A; Grathwohl S; Shokeen M; Zayed M; Gropler RJ; Abendschein D; Hawker CJ; Woodard PK
ACS Appl Mater Interfaces; 2019 May; 11(17):15316-15321. PubMed ID: 30969098
[TBL] [Abstract][Full Text] [Related]
5. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle.
Luehmann HP; Pressly ED; Detering L; Wang C; Pierce R; Woodard PK; Gropler RJ; Hawker CJ; Liu Y
J Nucl Med; 2014 Apr; 55(4):629-34. PubMed ID: 24591489
[TBL] [Abstract][Full Text] [Related]
6. Novel
Lucente E; Liu H; Liu Y; Hu X; Lacivita E; Leopoldo M; Cheng Z
Bioconjug Chem; 2018 May; 29(5):1595-1604. PubMed ID: 29587479
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET.
Liu Y; Abendschein D; Woodard GE; Rossin R; McCommis K; Zheng J; Welch MJ; Woodard PK
J Nucl Med; 2010 Jan; 51(1):85-91. PubMed ID: 20008978
[TBL] [Abstract][Full Text] [Related]
9. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
[TBL] [Abstract][Full Text] [Related]
10. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a ⁶⁴Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model.
Kim MH; Park JA; Woo SK; Lee KC; An GI; Kim BS; Kim KI; Lee TS; Kim CW; Kim KM; Kang JH; Lee YJ
Int J Oncol; 2015 Mar; 46(3):1159-68. PubMed ID: 25586565
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
Liu Y; Hu X; Liu H; Bu L; Ma X; Cheng K; Li J; Tian M; Zhang H; Cheng Z
J Nucl Med; 2013 Dec; 54(12):2132-8. PubMed ID: 24198391
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
Cai H; Li Z; Huang CW; Shahinian AH; Wang H; Park R; Conti PS
Bioconjug Chem; 2010 Aug; 21(8):1417-24. PubMed ID: 20666401
[TBL] [Abstract][Full Text] [Related]
17. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.
Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR
Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature.
Chen K; Sun X; Niu G; Ma Y; Yap LP; Hui X; Wu K; Fan D; Conti PS; Chen X
Mol Imaging Biol; 2012 Feb; 14(1):96-105. PubMed ID: 21360213
[TBL] [Abstract][Full Text] [Related]
19. Natriuretic peptide receptor a as a novel target for prostate cancer.
Wang X; Raulji P; Mohapatra SS; Patel R; Hellermann G; Kong X; Vera PL; Meyer-Siegler KL; Coppola D; Mohapatra S
Mol Cancer; 2011 May; 10():56. PubMed ID: 21586128
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
